The examination of the escape phenomenon of the disease modifying antirheumatic drugs

Yoichi Kawasaki, Masahiro Moriyama, Kazuhiko Shibata, Yutaka Gomita

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although disease-modifying antirheumatic drugs (DMARDs) are used in the treatment of rheumatoid arthritis (RA), the selection of agents in the case of relapse (escape phenomenon) lacks clear-cut standards. Therefore we investigated the rate and conditions of escape as well as the agents used after escapes had occurred. Outpatients of the Matsubara Mayflower Hospital with a history of DMARD administration during the 4 years prior to May 2003 were studied. Those receiving salazosulfapyridine (SASP) had a high escape rate and those receiving methotrexate (MTX) and bucillamine (BC) had a low rate. The continuous duration of administration was long for MTX and BC, but short for sodium aurothiomalate (GST). BC and Actarit (AR) gradually elevated C-reactive protein (CRP) levels and the erythrocyte sedimentation rate (ESR). In patients receiving SASP and MTX, a high level of CRP and high ESR was seen 2 months prior to the occurrence of escape and remained unchanged after escape. With respect to the agents used after escape, SASP and BC were substituted with other DMARDs. A combination with other DMARDs was usually administered to patients who had been receiving MTX. Taken together, the present results clarified the characteristics of DMARD escape and will contribute to the appropriate pharmacotherapy for RA.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalYakugaku Zasshi
Volume125
Issue number3
DOIs
Publication statusPublished - 2005

Fingerprint

Antirheumatic Agents
Methotrexate
Sulfasalazine
4-(acetylamino)benzeneacetic acid
Blood Sedimentation
C-Reactive Protein
Rheumatoid Arthritis
Gold Sodium Thiomalate
Outpatients
Recurrence
Drug Therapy
bucillamine

Keywords

  • C-reactive protein
  • Disease-modifying antirheumatic drugs
  • Erythrocyte sedimentation rate
  • Escape phenomenon
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

The examination of the escape phenomenon of the disease modifying antirheumatic drugs. / Kawasaki, Yoichi; Moriyama, Masahiro; Shibata, Kazuhiko; Gomita, Yutaka.

In: Yakugaku Zasshi, Vol. 125, No. 3, 2005, p. 293-297.

Research output: Contribution to journalArticle

Kawasaki, Yoichi ; Moriyama, Masahiro ; Shibata, Kazuhiko ; Gomita, Yutaka. / The examination of the escape phenomenon of the disease modifying antirheumatic drugs. In: Yakugaku Zasshi. 2005 ; Vol. 125, No. 3. pp. 293-297.
@article{e73b840f10a844d092d7f640b1f091c5,
title = "The examination of the escape phenomenon of the disease modifying antirheumatic drugs",
abstract = "Although disease-modifying antirheumatic drugs (DMARDs) are used in the treatment of rheumatoid arthritis (RA), the selection of agents in the case of relapse (escape phenomenon) lacks clear-cut standards. Therefore we investigated the rate and conditions of escape as well as the agents used after escapes had occurred. Outpatients of the Matsubara Mayflower Hospital with a history of DMARD administration during the 4 years prior to May 2003 were studied. Those receiving salazosulfapyridine (SASP) had a high escape rate and those receiving methotrexate (MTX) and bucillamine (BC) had a low rate. The continuous duration of administration was long for MTX and BC, but short for sodium aurothiomalate (GST). BC and Actarit (AR) gradually elevated C-reactive protein (CRP) levels and the erythrocyte sedimentation rate (ESR). In patients receiving SASP and MTX, a high level of CRP and high ESR was seen 2 months prior to the occurrence of escape and remained unchanged after escape. With respect to the agents used after escape, SASP and BC were substituted with other DMARDs. A combination with other DMARDs was usually administered to patients who had been receiving MTX. Taken together, the present results clarified the characteristics of DMARD escape and will contribute to the appropriate pharmacotherapy for RA.",
keywords = "C-reactive protein, Disease-modifying antirheumatic drugs, Erythrocyte sedimentation rate, Escape phenomenon, Rheumatoid arthritis",
author = "Yoichi Kawasaki and Masahiro Moriyama and Kazuhiko Shibata and Yutaka Gomita",
year = "2005",
doi = "10.1248/yakushi.125.293",
language = "English",
volume = "125",
pages = "293--297",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "3",

}

TY - JOUR

T1 - The examination of the escape phenomenon of the disease modifying antirheumatic drugs

AU - Kawasaki, Yoichi

AU - Moriyama, Masahiro

AU - Shibata, Kazuhiko

AU - Gomita, Yutaka

PY - 2005

Y1 - 2005

N2 - Although disease-modifying antirheumatic drugs (DMARDs) are used in the treatment of rheumatoid arthritis (RA), the selection of agents in the case of relapse (escape phenomenon) lacks clear-cut standards. Therefore we investigated the rate and conditions of escape as well as the agents used after escapes had occurred. Outpatients of the Matsubara Mayflower Hospital with a history of DMARD administration during the 4 years prior to May 2003 were studied. Those receiving salazosulfapyridine (SASP) had a high escape rate and those receiving methotrexate (MTX) and bucillamine (BC) had a low rate. The continuous duration of administration was long for MTX and BC, but short for sodium aurothiomalate (GST). BC and Actarit (AR) gradually elevated C-reactive protein (CRP) levels and the erythrocyte sedimentation rate (ESR). In patients receiving SASP and MTX, a high level of CRP and high ESR was seen 2 months prior to the occurrence of escape and remained unchanged after escape. With respect to the agents used after escape, SASP and BC were substituted with other DMARDs. A combination with other DMARDs was usually administered to patients who had been receiving MTX. Taken together, the present results clarified the characteristics of DMARD escape and will contribute to the appropriate pharmacotherapy for RA.

AB - Although disease-modifying antirheumatic drugs (DMARDs) are used in the treatment of rheumatoid arthritis (RA), the selection of agents in the case of relapse (escape phenomenon) lacks clear-cut standards. Therefore we investigated the rate and conditions of escape as well as the agents used after escapes had occurred. Outpatients of the Matsubara Mayflower Hospital with a history of DMARD administration during the 4 years prior to May 2003 were studied. Those receiving salazosulfapyridine (SASP) had a high escape rate and those receiving methotrexate (MTX) and bucillamine (BC) had a low rate. The continuous duration of administration was long for MTX and BC, but short for sodium aurothiomalate (GST). BC and Actarit (AR) gradually elevated C-reactive protein (CRP) levels and the erythrocyte sedimentation rate (ESR). In patients receiving SASP and MTX, a high level of CRP and high ESR was seen 2 months prior to the occurrence of escape and remained unchanged after escape. With respect to the agents used after escape, SASP and BC were substituted with other DMARDs. A combination with other DMARDs was usually administered to patients who had been receiving MTX. Taken together, the present results clarified the characteristics of DMARD escape and will contribute to the appropriate pharmacotherapy for RA.

KW - C-reactive protein

KW - Disease-modifying antirheumatic drugs

KW - Erythrocyte sedimentation rate

KW - Escape phenomenon

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=18244391468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244391468&partnerID=8YFLogxK

U2 - 10.1248/yakushi.125.293

DO - 10.1248/yakushi.125.293

M3 - Article

C2 - 15738628

AN - SCOPUS:18244391468

VL - 125

SP - 293

EP - 297

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 3

ER -